Federal health officials on Tuesday approved the first pill to treat all major forms of hepatitis C, the latest in a series of drug approvals that have reshaped treatment of the liver-destroying virus ...

After reviewing the evidence for all approved hepatitis C virus treatments, Advera Health has determined that Gilead Sciences’ newly approved, pan-genomic Epclusa has a similar safety profile as ...

The National Institute for Health and Care Excellence has now published final guidance endorsing Epclusa as an option for the treatment of adults with chronic hepatitis C genotype 1-6 infection on the ...

Credit: Getty Images. The expanded approval was based on data from an open-label phase 2 trial that evaluated Epclusa in 41 patients 3 years to less than 6 years of age with chronic HCV infection. The ...

TALLAHASSEE, Fla. (WCTV) -- Here's a question: how much would you pay for a life-changing prescription? The FDA is approving a brand new drug to cure Hepatitis C. Hep-C is a virus that attacks the ...

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved updated labeling for Epclusa (sofosbuvir 400mg/velpatasvir 100mg), the first all-oral, pan-genotypic, once ...

HealthDay News — The combination drug Epclusa has been approved by the US Food and Drug Administration to treat the 6 major strains of chronic hepatitis C virus. Epclusa combines sofosbuvir, ...

Gilead Sciences, Inc. (NASDAQ: GILD) revealed Tuesday that the Food and Drug Administration has approved its Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg). According to the company, this was the ...

Gilead Sciences has announced that the US Food and Drug Administration (FDA) has approved updated labeling for Epclusa (sofosbuvir 400mg/velpatasvir 100mg), the first all-oral, pan-genotypic, ...

Treatment with Epclusa for 12 weeks was approved in patients without cirrhosis or with compensated cirrhosis (Child-Pugh A), and in combination with ribavirin (RBV) for patients with decompensated ...

The U.S. Food and Drug Administration approved Epclusa to treat adult patients with chronic hepatitis C virus (HCV) both with and without cirrhosis (advanced liver disease). For patients with moderate ...